Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer Running title: Multiple-peptide vaccination for biliary tract cancer

Purpose: The prognosis of patients with advanced biliary tract cancer is extremely poor and there are only a few standard treatments. We performed a phase I trial to investigate the safety, immune response and anti-tumor effect of vaccination with four peptides derived from cancer-testis antigens, with a focus on their fluctuations during long-term vaccination until the disease had progressed. Experimental Design: Nine patients with advanced biliary tract cancer who had unresectable tumors and were refractory to standard chemotherapy were enrolled. HLA-A*2402-restricted epitope peptides, lymphocyte Research. on April 13, 2017. © 2013 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 11, 2013; DOI: 10.1158/1078-0432.CCR-12-3592